|
|
Behavioral factors are one of the key reasons for the development of pediatric functional constipation.2 Evidence suggests that stool-withholding behavior is the main etiological agent of functional constipation reported in 37%–91% of cases.3 |
 |
The stool-withholding maneuver leads to prolonged fecal stasis, causing harder, larger stools that increase pain, setting in a vicious cycle of stool retention and withholding.2 |
Impact of stool withholding on functional constipation pathogenesis2
 |
Withholding stool causes retention, hardeningit and raising the risk of impaction and overflow incontinence.2 |
| Stool withholding behavior, often triggered by painful bowel movements, is a key factor in FC development.2 |  |
 |
Painful defecation reinforces withholding behavior, creating a challenging cycle to break.2 |
 |
Fecal incontinence due to stool withholding can have a detrimental effect on a child’s and family’s quality of life.4 |
 |
Thus, educating parents about the negative effects of painful bowel movements and the role of withholding behavior and overflow incontinence is essential for the successful management of functional constipation.2 |
Abbreviations ▼
FC: Functional constipation; PEG: Polyethylene glycol.
References ▼
1. Pashankar DS, Loening-Baucke V, Bishop WP. Safety of polyethylene glycol 3350 for the treatment of chronic constipation in children. Arch Pediatr Adolesc Med. 2003;157(7):661–664. 2. Kesavelu D, Savla S, Savai J, et al. A cross-sectional survey on the perception of pediatricians about constipation in Indian pediatric patients (CROSCIP). Med Res Arch. 2023;11(7):1–9. 3. Tran DL, Sintusek P. Functional constipation in children: What physicians should know. World J Gastroenterol. 2023;29(8):1261–1288. 4. Koppen IJN, Benninga MA. Functional constipation and dyssynergic defecation in children. Front Pediatr. 2022;10:832877.
LMRC Code: GGI-CO-A1-AQS-300024228-ELC-I24-1577
For the use of a Registered Medical Practitioner, Hospital or Laboratory only.
Disclaimer:
The images are for illustrative representation only and do not depict actual medical products, procedures, or outcomes. Refer to official medical guidance and product information for accurate details.
All content including: text, images, audio, or other formats were created for medical educational purposes only. Offerings for continuing education are clearly identified and the appropriate target audience is identified. This communication is restricted for the use of HCPs and must not be shared in public domain. The opinions expressed in this video are solely the views of the speaker. The presentation may contain off label usage of drug(s) aimed at educational purpose only. Dr. Reddy’s Laboratories Ltd including but not limited its Affiliates strictly does not recommend any off label usage of its marketing products. Prior to treatment kindly refer to the latest prescribing information approved by the local authorities. No part of this content may be used, reproduced, transmitted or stored in any form without the written permission of Dr. Reddy’s.
